SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, Arora P, Sidarovich A, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S.
Hoffmann M, et al. Among authors: stankov mv.
Cell Rep. 2021 Jul 20;36(3):109415. doi: 10.1016/j.celrep.2021.109415. Epub 2021 Jun 29.
Cell Rep. 2021.
PMID: 34270919
Free PMC article.